Looking further, we expect Scientific revenue growth sequentially and year-on-year in fiscal '21 with approximately $10 million to $20 million of incremental sales to support COVID vaccine storage.
We are on track to deliver over $7 million in savings in fiscal 2021 from the actions we announced in the third quarter of fiscal 2020.
Specialty Solutions revenue and operating income decreased year-on-year, although is in line with our expectations that results would be sequentially similar to the fiscal fourth quarter of 2020.
As a result, our tax rate in fiscal 2021 is expected to be approximately 22% or 500 basis points lower than fiscal 2020.
As a result, our tax rate in fiscal '21 is expected to be approximately 22% or 500 basis points lower than fiscal 2020.
